Navigation

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) [ID473]

Erlotinib for the first line treatment of EGFR-TK mutation positive non-small-cell lung cancer

Status: History
Expected date of issue: June 2012
Referral date: July 2011
Process: STA
Notes:

Scoped within Batch 18

Topic area:
  • Cancer
  • Respiratory
 

NICE project team

Executive Lead: Carole Longson
Technical Lead: Bernice Dillon
Communications manager: Alice Law
Project manager: Rebecca Pye
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 10 October 2011
1st appraisal committee meeting: 24 January 2012
2nd appraisal committee meeting 22 March 2012
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Roche Products (erlotinib)

Patient/carer groups

  • Marie Curie Cancer Care
  • Roy Castle Lung Cancer Foundation

Professional groups

  • British Thoracic Society
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • NHS Derby City
  • Welsh Government

 

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland
  • Public Health Wales NHS Trust

Comparator manufacturers

  • AstraZeneca (gefitinib)
  • Eli Lilly (pemetrexed)
  • Goldshield Pharmaceuticals (cisplatin) (Confidentiality agreement not signed, not participating)
  • Hospira UK (carboplatin, cisplatin) (Confidentiality agreement not signed, not participating)
  • Pfizer (cisplatin)
  • Sandoz (carboplatin, cisplatin) (Confidentiality agreement not signed, not participating)
  • Sun Pharmaceuticals (carboplatin) (Confidentiality agreement not signed, not participating)
  • Teva UK (carboplatin, cisplatin) (Confidentiality agreement not signed, not participating)
  • Wockhardt UK (carboplatin, cisplatin) (Confidentiality agreement not signed, not participating)

Relevant research groups

  • British Thoracic Oncology Group

Evidence Review Group

  • Liverpool Reviews and Implementation Group (LRIG)
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • National Collaborating Centre for Cancer

Associated public health groups

  • None

 

Top


 

Key documents

This page was last updated: 27 June 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.